Johnson & Johnson $JNJ Shares Acquired by Jones Financial Companies Lllp

Jones Financial Companies Lllp increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 745,052 shares of the company’s stock after acquiring an additional 80,182 shares during the period. Jones Financial Companies Lllp’s holdings in Johnson & Johnson were worth $134,611,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. United Bank raised its stake in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. grew its stake in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares in the last quarter. Finally, Barrett & Company Inc. increased its holdings in Johnson & Johnson by 1.1% during the 2nd quarter. Barrett & Company Inc. now owns 9,710 shares of the company’s stock worth $1,483,000 after purchasing an additional 105 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Loop Capital set a $220.00 price objective on Johnson & Johnson in a research note on Tuesday, January 27th. Bank of America boosted their price target on shares of Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a report on Thursday, January 22nd. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Finally, Barclays raised their price target on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.05.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $230.82 on Tuesday. The company has a fifty day moving average of $211.21 and a two-hundred day moving average of $192.24. The company has a market capitalization of $556.11 billion, a PE ratio of 20.89, a P/E/G ratio of 2.21 and a beta of 0.35. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $231.19. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The business had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.